Item | n (%) |
---|---|
Usual OCPs being used by the participants | Â |
 Ethinylestradiol/drospirenone | 209 (47.6) |
 Ethinylestradiol/cyproterone acetate | 70 (16) |
 Ethinylestradiol/levonorgestrel | 42 (9.6) |
 Ethinylestradiol/desogestrel) | 41 (9.3) |
 Dydrogesterone | 30 (6.8) |
 Norethindrone | 25 (5.6) |
 Ethinylestradiol/dienogest | 9 (2) |
 Desogestrel | 7 (1.6) |
 Progesterone | 5 (1.1) |
 Norgestrel/estradiol) | 2 (0.4) |
Indication | Â |
 Contraception (birth control) | 177 (40.5) |
 Period regulation | 116 (26.1) |
 Polycystic ovarian syndrome | 96 (21.8) |
 Primary dysmenorrhea | 7 (1.6) |
 Endometriosis | 7 (1.6) |
 Others | 37 (8.4) |
Duration of administration | Â |
 Intermittently | 25 (5.7) |
 ≤ 3 months | 104 (23.6) |
 > 3 months to ≤ 6 months | 65 (14.7) |
 > 6 months to ≤ 1 year | 72 (16.3) |
 > 1 year to ≤ 2 years | 39 (8.9) |
 > 2 years to ≤ 3 years | 21 (4.8) |
 > 3 years | 114 (26) |
Stockpiling behavior of preferred brands during the shortage period | Â |
 No | 315 (71.6) |
 Yes | 125 (28.4) |
Availability of preferred brands in the pharmacies | Â |
 No | 336 (76.4) |
 Yes | 104 (23.6) |
Duration of unavailability of preferred brands in the pharmacies (n = 336) |  |
  ≤ 3 months | 110 (32.7) |
 > 3 months to 6 months | 125 (37.2) |
 > 6 months to < 1 year | 57 (17) |
  ≥ 1 year | 44 (13.1) |